Drug intelligence / Profile preview

DNL111

Development stage: Preclinical
Lead developer: Denali Therapeutics
Modality: Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

DNL111 (ETV:GCase) is an investigational enzyme transport vehicle therapy developed by Denali Therapeutics. It is designed to deliver the enzyme glucocerebrosidase (GCase) across the blood-brain barrier using Denali’s proprietary Enzyme Transport Vehicle (ETV) technology. The primary aim of DNL111 is to address central nervous system manifestations in diseases associated with GCase deficiency, such as Parkinson's disease and Gaucher disease. By restoring GCase activity in the brain, DNL111 targets lysosomal dysfunction implicated in these neurodegenerative and lysosomal storage disorders[3][4][1].

Other names: ETV:GCase

Targets

GBA1 (Glucosylceramidase)

Beyond the preview

Go deeper on DNL111.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNL111.

Explore the full profile